跳到正文
FDA 官方药品与生物制品信息·· 14 天前AI 评分29

FDA 仿制药办公室科学与研究项目及 2026 年研讨会安排

Science & Research | Generic Drugs

AI 导读

FDA 仿制药办公室下属研究与标准办公室依托 GDUFA 设立的科学与研究项目,与业界和公众合作制定仿制药监管科学年度倡议清单,研究成果用于评估仿制药等效性并支持企业开发仿制药。页面列出研究重点与项目、指南与报告,并公布 2026 年 8 月至 12 月的多场研讨会,涉及长效注射剂、吸入制剂、GLP-1 仿制药路径、局部及透皮制剂生物等效性等主题。

正文 · 原文

Decorative graphic of scientists on laptop computers

The Office of Research and Standards, within the FDA's Office of Generic Drugs (OGD), supports the Science and Research program established under the Generic Drug User Fee Amendments (GDUFA). In collaboration with industry and the public, FDA creates an annual list of regulatory science initiatives on generic drugs. The research studies conducted under these initiatives advance public health by contributing to the development of safe and effective generic drugs. The results provide new tools for FDA to evaluate generic drug equivalence and for industry to efficiently develop new generic products.

decorative icon image for Generic Drugs Priorities and Projects

Priorities & Projects

Learn more about FDA generic drug research priorities, public workshops, and awarded projects.

Decorative icon for Generic Drugs Guidances & Reports

Guidances & Reports

View FDA generic drug research publications, including product-specific guidances and annual reports.

Generic Drugs Research Publications & Resources

Decorative icon image for Generic Drugs Collaboration Opportunities

Latest Science & Research News

来源:FDA 官方药品与生物制品信息 · fda.gov